Log In
BCIQ
Print this Print this
 

ADAP NY-ESO TCR, NY-ESO SPEAR T-cell therapy (GSK3377794)

Also known as: enhanced T-cell therapy targeting NY-ESO-1 (formerly Enhanced TCR therapy targeting NY-ESO-1)

  Manage Alerts
Collapse Summary General Information
Company Adaptimmune Therapeutics plc
DescriptionAutologous T cells genetically modified to express T cell receptors (TCR) targeting cancer/testis antigen 1B (NY-ESO-1; CTAG1B)
Molecular Target Cancer/testis antigen 1B (NY-ESO-1) (CTAG1B)
Mechanism of Action 
Therapeutic ModalityActive immunotherapy

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/27/2016

Undisclosed

Undisclosed

Undisclosed

06/02/2014

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today